Here is the design of a clinical trial:

Official Title: Protocol for Rationale and Design of Home-Based SolUtion for Remote Atrial Fibrillation Screening to PrevenT RecUrrence StrOke (HUA-TUO AF Trial): A Randomized Open-label Study

Included conditions:
- Stroke, Cardiovascular

Study Armgroups:
- {'label': 'Home-based atrial fibrillation screening group', 'type': 'EXPERIMENTAL', 'description': 'Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.', 'interventionNames': ['Device: Remote atrial fibrillation screening with handheld single lead ECG recorder']}
- {'label': 'Control group', 'type': 'NO_INTERVENTION', 'description': 'Conventional medical care'}

Interventions:
- {'type': 'DEVICE', 'name': 'Remote atrial fibrillation screening with handheld single lead ECG recorder', 'description': 'Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.', 'armGroupLabels': ['Home-based atrial fibrillation screening group']}

Primary Outcomes:
- {'measure': 'First detection of AF', 'description': 'First detection of AF by the handheld ECG, defined as an episode of irregular heart rhythm, without detectable P waves, lasting more than 30 seconds', 'timeFrame': '2 years'}

Please estimate the sample size based on the assumption: 
90% power, significance level of p<0.05, and an attrition rate of 15%.
Sample size calculation
        The primary analysis is to test whether home-based AF screening is superior to conventional care to detect new-onset AF. A total sample size of 1740 patients who had stroke is expected to achieve 90% power to detect a statistically significant difference (p<0.05) in time to first documented AF episode at 24 months. The sample size calculation is based on cumulative AF detection of 4% (2% per year) in the control group and 8% (4% per year) in the home-based AF screening group at 2 years. An attrition rate of 15% is accounted for in this sample size.